Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR

Bone Marrow Transplantation

Volumn 45, Issue 7, 2010, Pages 1256-1258

  Kohli, R ^a   Xu, W ^b   Brandwein, J ^a   Minden, M D ^a   Schimmer, A ^a   Schuh, A C ^a   Lipton, J H ^a   Yee, K ^a   Messner, H A ^a   Gupta, V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; STEROID; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; BONE DENSITY; BONE NECROSIS; CARDIOVASCULAR RISK; CATARACT; DIABETES MELLITUS; DISEASE FREE SURVIVAL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; OPHTHALMOPLEGIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; HUMANS; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955013504     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.324     Document Type: Letter

References (9)

1. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833.
2. Gupta V, Yi QL, Brandwein J, Minden MD, Schuh AC, Wells RA et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant 2004; 33: 397-404.
3. Sebban C, Lepage E, Vernant JP, Gluckman E, Attal M, Reiffers J et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994; 12: 2580-2587.
4. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075-4086. (Pubitemid 41185176)
5. Calissendorff BM, Lonnqvist B, el Azazi M. Cataract development in adult bone marrow transplant recipients. Acta Ophthalmol Scand 1995; 73: 152-154.
6. Fahnehjelm KT, Tornquist AL, Olsson M, Winiarski J. Visual outcome and cataract development after allogeneic stem-cell transplantation in children. Acta Ophthalmol Scand 2007; 85: 724-733.
7. Tauchmanova L, Serio B, Del Puente A, Risitano AM, Esposito A, De Rosa G et al. Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2002; 87: 5058-5065.
8. Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007; 110: 3463-3471.
9. Tichelli A, Passweg J, Wojcik D, Rovo A, Harousseau JL, Masszi T et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93: 1203-1210.